{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:38:27Z","timestamp":1789843107849,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.schres.2020.04.031","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T07:39:29Z","timestamp":1591083569000},"page":"88-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"222","author":[{"given":"Javier","family":"Labad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Montalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Garc\u00eda-Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Palao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.04.031_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2004-827176","article-title":"Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report","volume":"37","author":"Bliesener","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.genhosppsych.2011.07.004","article-title":"The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis","volume":"34","author":"Broekhof","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0020","series-title":"Antipsychotic-induced Hyperprolactinaemia - Trust Guideline for Identification, Monitoring and Management","author":"Brown","year":"2013"},{"key":"10.1016\/j.schres.2020.04.031_bb0025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4088\/JCP.08l04671","article-title":"Aripiprazole treatment of risperidone-induced hyperprolactinemia","volume":"70","author":"Chen","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0040","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","article-title":"Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series","volume":"65","author":"Chen","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2020.04.031_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.04.031_bb0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/157488612802715753","article-title":"Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics","volume":"7","author":"Coronas","year":"2012","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.schres.2020.04.031_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004714-198704000-00008","article-title":"Amantadine in the treatment of neuroendocrine side effects of neuroleptics","volume":"7","author":"Correa","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1017\/S2045796016000809","article-title":"Pre-post effect sizes should be avoided in meta-analyses","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.schres.2020.04.031_bb0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00737-018-0899-x","article-title":"Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients","volume":"22","author":"Delgado-Alvarado","year":"2019","journal-title":"Arch. Womens. Ment. Health"},{"key":"10.1016\/j.schres.2020.04.031_bb0075","first-page":"74","article-title":"Effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia: a preliminary open-label study","volume":"50","author":"Fujioi","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2011.07.025","article-title":"Prolactin concentrations in newly diagnosed, antipsychotic-na\u00efve patients with nonaffective psychosis","volume":"134","author":"Garcia-Rizo","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.04.031_bb0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2016.03.018","article-title":"Prolactin concentrations in antipsychotic-naive patients with schizophrenia and related disorders: a meta-analysis","volume":"174","author":"Gonzalez-Blanco","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.04.031_bb0090","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","article-title":"Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research","volume":"234","author":"Grigg","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2020.04.031_bb0095","first-page":"278","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta","year":"2017","journal-title":"B J Psych Adv"},{"key":"10.1016\/j.schres.2020.04.031_bb0100","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2020.04.031_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.04.031_bb0110","first-page":"1571","article-title":"The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study","volume":"10","author":"Hashimoto","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2020.04.031_bb0115","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [WWW Document]","year":"2011"},{"key":"10.1016\/j.schres.2020.04.031_bb0120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/JCP.0b013e31820f4fbd","article-title":"Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia","volume":"31","author":"Ishitobi","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.schres.2017.02.010","article-title":"Sex differences in prolactin levels in emerging psychosis: indication for enhanced stress reactivity in women","volume":"189","author":"Ittig","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.04.031_bb0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1037\/a0033448","article-title":"Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients","volume":"21","author":"Kalkavoura","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0140","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/WNF.0000000000000006","article-title":"Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series","volume":"36","author":"Kawabe","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0150","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0000000000000898","article-title":"Adjunct aripiprazole reduces prolactin and prolactin-related adverse effects in premenopausal women with psychosis: results from the DAAMSEL clinical trial","volume":"38","author":"Kelly","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.04.031_bb0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.psyneuen.2018.11.028","article-title":"The role of cortisol and prolactin in the pathogenesis and clinical expression of psychotic disorders","volume":"102","author":"Labad","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.04.031_bb0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14656566.2017.1288722","article-title":"How gender affects the pharmacotherapeutic approach to treating psychosis\u2013a systematic review","volume":"18","author":"Lange","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2020.04.031_bb0170","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","article-title":"Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study","volume":"30","author":"Lee","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0175","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.psyneuen.2011.04.007","article-title":"Prolactin in response to acute psychosocial stress in healthy men and women","volume":"36","author":"Lennartsson","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2020.04.031_bb0180","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2020.04.031_bb0185","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0190","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.schres.2020.04.031_bb0195","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2020.04.031_bb0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e32835ba832","article-title":"Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate","volume":"28","author":"Montalvo","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0205","first-page":"158","article-title":"Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia","volume":"9","author":"Montejo","year":"2016","journal-title":"Rev. Psiquiatr. y Salud Ment. (English Ed)"},{"key":"10.1016\/j.schres.2020.04.031_bb0210","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0215","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1094428106291059","article-title":"Estimating effect sizes from pretest-posttest-control group designs","volume":"11","author":"Morris","year":"2008","journal-title":"Organ. Res. Methods"},{"key":"10.1016\/j.schres.2020.04.031_bb0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2005-837766","article-title":"Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia","volume":"38","author":"Nakajima","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2020.04.031_bb0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.psychres.2015.12.033","article-title":"Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone","volume":"237","author":"Qiao","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.04.031_bb0235","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-R\u00f6ssler","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2020.04.031_bb0240","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-198101000-00002","article-title":"The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients","volume":"1","author":"Siever","year":"1981","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0250","series-title":"Abstracts of the 20th Cochrane Colloquium","article-title":"Can data extraction from figures perform a meta-analysis?","author":"Silva","year":"2012"},{"key":"10.1016\/j.schres.2020.04.031_bb0255","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/ajo.12479","article-title":"Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: a systematic review","volume":"56","author":"Snellen","year":"2016","journal-title":"Aust. New Zeal. J. Obstet. Gynaecol."},{"key":"10.1016\/j.schres.2020.04.031_bb0260","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/jnp.15.3.375","article-title":"Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea","volume":"15","author":"Takahashi","year":"2003","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2020.04.031_bb0265","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2018"},{"key":"10.1016\/j.schres.2020.04.031_bb0270","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/bmj.289.6452.1101","article-title":"Psychotic reactions during treatment of pituitary tumours with dopamine agonists","volume":"289","author":"Turner","year":"1984","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2020.04.031_bb0275","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","article-title":"Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection","volume":"31","author":"Van Kooten","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"Von Hippel","year":"2015","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.schres.2020.04.031_bb0285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.schres.2020.04.031_bb0290","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","article-title":"Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"169","author":"Wu","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.04.031_bb0295","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0300","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","article-title":"Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study","volume":"39","author":"Yoon","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0305","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","article-title":"A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia","volume":"28","author":"Yuan","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0310","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2020.04.031_bb0315","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881117699630","article-title":"Adjunctive metformin for antipsychotic-related hyperprolactinemia: a meta-analysis of randomized controlled trials","volume":"31","author":"Zheng","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.04.031_bb0320","article-title":"Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis","volume":"32","author":"Zheng","year":"2019","journal-title":"Gen. Psychiatry."},{"key":"10.1016\/j.schres.2020.04.031_bb0325","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","article-title":"Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection","volume":"33","author":"Ziadi Trives","year":"2013","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420302383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420302383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:10Z","timestamp":1760297710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420302383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":65,"alternative-id":["S0920996420302383"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.04.031","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}